Cargando…

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

The identification of specific biomarkers that recognize the functional drivers of heterogeneity in prostate cancer (PCa) and personalized treatment remain challenging in systemic medicine. Liquid biopsy allows for the detection and analysis of personalized predictive biomarkers in single blood samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theil, Gerit, Lindner, Carlotta, Bialek, Joanna, Fornara, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307979/ https://www.ncbi.nlm.nih.gov/pubmed/34357036 http://dx.doi.org/10.3390/life11070664

Ejemplares similares

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2022)

Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients
por: Theil, Gerit, et al.
Publicado: (2020)

In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer
por: Theil, Gerit, et al.
Publicado: (2021)

Potential Use of CTCs as Biomarkers in Renal Cancer Patients
por: Bialek, Joanna, et al.
Publicado: (2022)

Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer
por: Bialek, Joanna, et al.
Publicado: (2021)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study
por: Theil, Gerit, et al.
Publicado: (2016)

The Adipocyte-Derived Hormone Leptin Has Proliferative Actions on Androgen-Resistant Prostate Cancer Cells Linking Obesity to Advanced Stages of Prostate Cancer
por: Hoda, M. Raschid, et al.
Publicado: (2012)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
por: Magbanua, Mark Jesus M, et al.
Publicado: (2012)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2015)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Correction: Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2017)

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Wang, Chun, et al.
Publicado: (2021)

Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
por: Chung, Jae-Seung, et al.
Publicado: (2019)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Liaw, Bobby C, et al.
Publicado: (2022)

Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital
por: Fosså, Sophie D, et al.
Publicado: (2014)

Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients
por: Cho, Won Jin, et al.
Publicado: (2016)

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Maillet, Denis, et al.
Publicado: (2021)

Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2020)

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer
por: Chang, Kun, et al.
Publicado: (2015)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2017)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
por: De Laere, Bram, et al.
Publicado: (2021)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
por: Kwan, Edmond M., et al.
Publicado: (2021)

PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
por: Markou, Athina, et al.
Publicado: (2020)

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
por: Chong, Weelic, et al.
Publicado: (2021)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a9bfl6k13stkna9htl6qip8nen